Significant prevalence of antibodies reacting with simian virus 40 mimotopes in sera from patients affected by glioblastoma multiforme

Neuro-Oncology

Volumn 16, Issue 4, 2014, Pages 513-519

  Mazzoni, Elisa ^a   Gerosa, Massimo ^b   Lupidi, Francesco ^b   Corallini, Alfredo ^c   Taronna, Angelo Pio ^c   D'Agostino, Antonio ^b   Bovenzi, Massimo ^d   Ruggeri, Giuseppina ^g   Casali, Ferruccio ^f   Rotondo, John Charles ^a   Rezza, Giovanni ^e   Barbanti Brodano, Giuseppe ^c   Tognon, Mauro ^a   Martini, Fernanda ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

^e City Hospital   (Italy)

^f Department of Anesthesia and Intensive Care   (United States)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Glioblastoma multiforme; Immunglobulin G; Simian virus 40

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; SYNTHETIC PEPTIDE;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; BRAIN TUMOR; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SERUM; SIMIAN VIRUS 40;

GLIOBLASTOMA MULTIFORME; IMMUNGLOBULIN G; SIMIAN VIRUS 40;

ADULT; ANTIBODIES, VIRAL; BREAST NEOPLASMS; CAPSID PROTEINS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; ITALY; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREVALENCE; PROGNOSIS; SIMIAN VIRUS 40;

EID: 84897007078     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not217     Document Type: Article

References (39)

1. Gulati S, Jakola AS, Johannesen TB, Solheim O. Survival and treatment patterns of glioblastoma in the elderly: a population-based study. World Neurosurg. 2012;78(5):518-526.
2. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479-489.
3. Sant M, Minicozzi P, Lagorio S, Borge Johannesen T, Marcos-Gragera R, Francisci S. Survival of European patients with central nervous system tumors. Int J Cancer. 2012;131(1):173-185.
4. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002;4(4):278-299.
5. Smoll NR, Schaller K, Gautschi OP. The cure fraction of glioblastoma multiforme. Neuroepidemiology. 2012;39(1):63-69.
6. Martini F, Corallini A, Balatti V, Sabbioni S, Pancaldi C, Tognon M. Simian virus 40 in humans. Infect Agent Cancer. 2007;2:13.
7. Barbanti-Brodano G, Sabbioni S, Martini F, Negrini M, Corallini A, Tognon M. Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology. 2004;318(1):1-9.
8. Saenz-Robles MT, Sullivan CS, Pipas JM. Transforming functions of simian virus 40. Oncogene. 2001;20(54):7899-7907.
9. Martini F, Iaccheri L, Lazzarin L, et al. SV40 early region and large T antigen in human brain tumors, peripheral blood cells, and sperm fluids from healthy individuals. Cancer Res. 1996;56(20):4820-4825.
10. Martini F, Lazzarin L, Iaccheri L, et al. Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA ofhumanbrain and bone tumors and of leukocytes fromblood donors. Cancer. 2002;94(4):1037-1048.
11. Pancaldi C, Balatti V, Guaschino R, et al. Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution. J Infect. 2009; 58(1):53-60.
12. Engels EA, Sarkar C, Daniel RW, et al. Absence of simian virus 40 in human brain tumors from northern India. Int J Cancer. 2002;101(4): 348-352.
13. Rollison DE, Helzlsouer KJ, Alberg AJ, et al. Serum antibodies to JCvirus, BK virus, simian virus 40, and the risk of incident adult astrocytic brain tumors. Cancer Epidemiol Biomarkers Prev. 2003;12(5):460-463.
14. Rollison DE, Utaipat U, Ryschkewitsch C, et al. Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. Int J Cancer. 2005;113(5):769-774.
15. Klein G, Powers A, Croce C. Association of SV40 with human tumors. Oncogene. 2002;21(8):1141-1149.
16. Carbone M, Bocchetta M, Cristaudo A, et al. SV40 and human brain tumors. Int J Cancer. 2003;106(1):140-142; author reply 143-145.
17. Carbone M, Rdzanek MA, Rudzinski JJ, et al. SV40 detection in human tumor specimens. Cancer Res. 2005;65(21):10120-10121.
18. Viscidi RP, Rollison DE, Viscidi E, et al. Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol. 2003;10(2):278-285.
19. Carter JJ, Madeleine MM, Wipf GC, et al. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst. 2003;95(20):1522-1530.
20. Barbanti-Brodano G, Corallini A, Accolla RS, Martini F, Tognon M. Re: lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst. 2004;96(10):803-804; author reply 804-805.
21. Lundstig A, Eliasson L, Lehtinen M, Sasnauskas K, Koskela P, Dillner J. Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles. J Gen Virol. 2005;86(Pt 6):1703-1708.
22. Kjaerheim K, Roe OD,Waterboer T, et al. Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples. Int J Cancer. 2007;120(11):2459-2465.
23. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5(3):e1000363.
24. Ribeiro T, Fleury MJ, Granieri E, et al. Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis. Neurol Sci. 2010;31(4): 517-521.
25. Taronna A, Mazzoni E, Corallini A, et al. Serological evidence of an early seroconversion to simian virus 40 in healthy children and adolescents. PloS One. 2013;8(4):e61182.
26. Corallini A, Mazzoni E, Taronna A, et al. Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors. Hum Immunol. 2012;73(5):502-510.
27. Mazzoni E, Tognon M, Martini F, et al. Simian virus 40 (SV40) antibodies in elderly subjects. The Journal of infection. 2013;67(4): 356-358.
28. Mazzoni E, Corallini A, Cristaudo A, et al. High prevalence of serum antibodies reacting with simian virus 40 capsid protein mimotopes in patients affected by malignant pleural mesothelioma. Proc Natl Acad Sci U S A. 2012;109(44):18066-18071.
29. Martini F, Mazzoni E, Corallini A, et al. Breast cancer and simian virus 40 infection. Epidemiology. 2013;24(3):464-465.
30. Guerrini R, Salvadori S, Rizzi A, Regoli D, Calo G. Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev. 2010;30(5):751-777.
31. Major EO, Miller AE, Mourrain P, Traub RG, de Widt E, Sever J. Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci U S A. 1985;82(4):1257-1261.
32. Martini F, DeMattei M, Iaccheri L, et al.Humanbrain tumors and simian virus 40. J Natl Cancer Inst. 1995;87(17):1331.
33. Barbanti-Brodano G, Martini F, De Mattei M, Lazzarin L, Corallini A, Tognon M. BK and JC human polyomaviruses and simian virus 40: natural history of infection in humans, experimental oncogenicity, and association with human tumors. Adv Virus Res. 1998;50:69-99.
34. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol. 2003;71(1):115-123.
35. Vanchiere JA, Abudayyeh S, Copeland CM, Lu LB, Graham DY, Butel JS. Polyomavirus shedding in the stool of healthy adults. J Clin Microbiol. 2009;47(8):2388-2391.
36. Patel NC, Vilchez RA, Killen DE, et al. Detection of polyomavirus SV40 in tonsils from immunocompetent children. J Clin Virol. 2008;43(1): 66-72.
37. Vanchiere JA, White ZS, Butel JS. Detection of BK virus and simian virus 40 in the urine of healthy children. J Med Virol. 2005;75(3):447-454.
38. Morris JA, Johnson KM, Aulisio CG, Chanock RM, Knight V. Clinical and serologic responses in volunteers given vacuolating virus (SV-40) by respiratory route. Proc Soc Exp Biol Med. 1961;108:56-59.
39. Melnick JL, Stinebaugh S. Excretion of vacuolating SV-40 virus (papova virus group) after ingestion as a contaminant of oral poliovaccine. Proc Soc Exp Biol Med. 1962;109:965-968.